Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

LEAP THERAPEUTICS, INC. (LPTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Leap Therapeutics Reports Second Quarter 2023 Financial Results"
07/12/2023 8-K Quarterly results
05/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting"
05/15/2023 8-K Quarterly results
Docs: "Leap Therapeutics Reports First Quarter 2023 Financial Results"
04/26/2023 8-K Quarterly results
03/24/2023 8-K Quarterly results
Docs: "Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results"
03/16/2023 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submiss...
Docs: "CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATION OF SPECIAL VOTING STOCK OF LEAP THERAPEUTICS, INC.",
"Option and License Agreement”), by and between Leap Therapeutics, Inc., a Delaware corporation , and BeiGene, Ltd., a Cayman Island exempted company incorporated with limited liability , that certain Clinical Manufacturing and Supply Agreement, dated as of April 23, 2020, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof , that certain Clinical Quality Agreement, dated as of May 3, 2020, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof , and that certain First Amended and Restated Pharmacovigilance Agreement, dated as of October 12, 2022, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof . The Option an...",
"Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01"
01/23/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "AGREEMENT AND PLAN OF MERGER",
"LEAP THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X NON-VOTING CONVERTIBLE PREFERRED STOCK",
"THIS SUPPORT AGREEMENT , dated as of January 17, 2023, is made by and among Leap Therapeutics, Inc., a Delaware corporation , and HealthCare Ventures IX, L.P., a Delaware limited partnership (“Stockholder",
"Execution Version",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made as of January 17, 2023, by and among Leap Therapeutics, Inc., a Delaware corporation , and those persons that as of the date of this Agreement become or have become entitled to receive Registrable Securities pursuant to, and in accordance with, the Merger Agreement and become parties to this Agreement by executing and delivering a counterpart signature page to this Agreement on the date of this Agreement or on any date thereafter . Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1 . RECITALS WHEREAS, pursuant to, and in accordance with, that certain Agreement and Plan of Merger, dated as of the date hereof, by and among the Company, Fir..."
01/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
11/14/2022 8-K Quarterly results
11/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting"
11/04/2022 8-K Quarterly results
09/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors",
"Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq ® at the ESMO Congress"
08/12/2022 8-K Quarterly results
Docs: "Leap Therapeutics Reports Second Quarter 2022 Financial Results",
"Leap Therapeutics’ Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute"
07/12/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
03/11/2022 8-K Quarterly results
Docs: "Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results"
01/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium"
11/12/2021 8-K Quarterly results
Docs: "Leap Therapeutics Reports Third Quarter 2021 Financial Results"
09/24/2021 8-K Quarterly results
09/22/2021 8-K Quarterly results
09/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants",
"Company Overview September 2021"
09/16/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
08/13/2021 8-K Quarterly results
Docs: "Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation"
06/16/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
04/01/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Leap Therapeutics Reports Third Quarter 2020 Financial Results"
11/09/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Leap Therapeutics Presents Updated Data for DKN-01 in Esophagogastric Cancer Patients at SITC 2020 35 th Annual Meeting",
"Leap Therapeutics Presents DKN-01 Monotherapy Data at AACR Virtual Special Endometrial Cancer Conference"
09/24/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy